Susquehanna International Group, LLP Acurx Pharmaceuticals, Inc. Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 69,745 shares of ACXP stock, worth $290,836. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,745Holding current value
$290,836% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding ACXP
# of Institutions
37Shares Held
2.71MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$4.5 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.53 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$610,5040.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA146KShares$606,8890.0% of portfolio
-
Morgan Stanley New York, NY106KShares$442,8580.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $48.2M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...